Our investment focus is the healthcare industry with an emphasis on therapeutics, diagnostics, and digital health. We source most of our deals from the U.S., Europe and China. We are always interested in discussing new investment opportunities, but successful biotechnology companies usually have an experienced management team, strong intellectual property position, address a vital market need and provide an opportunity for a strong financial exit.

Our investment philosophy is to be integrally involved in our portfolio companies at every level of corporate and business development. We will provide the strategic and operational support these companies require to succeed. This approach also gives our investors of confidence in our investment choices and reaffirms our commitment to deliver anticipated financial outcomes. Our management team has an extensive background in both healthcare industry and academia spanning every step of technology development and commercialization.

We typically invest in early stage biotechnology and medical device companies with novel and proprietary technologies that are driven by strong and experienced management teams. Julz often acts as the lead investor and will have board representation on each of the portfolio companies but will syndicate the round based on the opportunity and partners.

We derive our growth mainly from U.S. and European markets. Our portfolio companies, however, must have market opportunities in Asian markets, especially in China. China is the second largest economy in the world, but it lags behind other developed countries in healthcare expenditures and we see tremendous opportunity for growth in this sector. We are well positioned to provide support for market entry into China in the healthcare sector.